CCX

This week, Head of Commercial Cole Boskey had the opportunity to speak and attend the Cell & Gene Therapy Pricing Reimbursement Summit. During his talk, Cole covered 4 issues CCX has worked on with clients: 1. Early Payer Engagement 2. HQ & Affiliate Collaboration 3. Single source of Truth and 4. Rapid Negotiation. Do any of these sound like challenges you are facing? We would love to talk to you about our solutions!

AT #ISPOR last week there was some fantastic content about how to think about AI in #MarketAccess and #HEOR. I’d like to share some thoughts on how we as an access ecosystem build toward AI informed in part by the excellent presentations by Ipek Özer Stillman Rachael Fleurence, Ph.D. Sanatan Shreay, Jagpreet (Jag) Chhatwal, Turgay Ayer, Francesco Di Marco, Steven Laux, James Cremens, Adrienne Lovink, Eric Wu, Jimmy Royer, Rajeev Ayyagari, and others. I look forward to continuing this journey together as we advance market access using all the tools available to us, #AI and otherwise. ISPOR—The Professional Society for Health Economics and Outcomes Research

On May 1st, Professor Christopher McCabe and Dr Felicity Lamrock of Queen's University Belfast organized an excellent event bringing together leaders from academia and market access to share our learnings and compare notes. Dr. James Francis O'Mahony from University College Dublin spoke about opportunity cost and evidence-based thresholds. Building on this, Dr. Mike Paulden from University of Alberta shared a framework for fair pricing involving implications for population health and opportunity cost. Dr. Jeff Round from IHE and University of Alberta shared about risk – Recognizing that there’s diversity in payers wanting to internalize risk or wanting to eliminate risk with implications for access solutions. Dr. Roisin Adams from the National Centre Pharmacoeconomics in Dublin- spoke about the practicalities of bringing theory to life – especially the transformational work of multi-regional HTA. I shared some of my team’s learnings in streamlining negotiations and the administration of access agreements. And Chris did a great job of weaving all this together and sparking lively discussion. It was great to have academics, payers, regulators, industry leaders together in one place. Reconnecting with old friends and and getting to know some new ones. Really nicely done Chris, Felicity, and all the others involved in this event!

How #technology is helping to fundamentally transform #marketaccess in Europe and elsewhere: Part 4 of my series on why I'm bullish on market access in Europe

The nature of #leverage in #marketaccess negotiations is changing, and that's one of the reasons I'm bullish on the future of Market Access in Europe. #HTA #heor #pricingandreimbursement #pharma CCX

Thanks to everyone who joined the CCX reception last night after a great Day 1 of #epaconf

Hard at work at the 2024 #EPAConf. Stop by booth 142 and see us!

CCX will be participating at World Evidence, Pricing and Access Congress next week and our advisors @Mel Walker and @Carole Longson will join a panel Tuesday on “Accelerating access to innovative medicines in the UK: Key strategic themes for global access leaders.” This session will explore some of the major barriers and key opportunities to innovate #market access in the UK, with key learnings applicable to the broader European and global markets.  Many of the challenges present in the UK we see in different markets, with questions on data, clinical strategy, and other complex challenges market access teams are facing. Confirmed panelists for this session are: ·      Robert Kettell Director of Medicines Negotiation and Managed Access, NHS England; Government Negotiator for VPAG ·      Elena Tricca, Vice President, Global Market Access and Pricing, BioPharmaceuticals, AstraZeneca ·      Prof Carole Longson, Vice Chair, Medicines Discovery Catapult; Professor of Health Technology Assessment, Manchester University ·      Prof Christopher Kipps, Member, National NHS Research SDE Network; Clinical R&D Director; Consultant Neurologist If you are planning on attending #EPAConf, join us for this panel, share your thoughts and meet our team – look forward to seeing you there! #EPAConf #marketaccess #pricing

Why I'm bullish on European market access: how #JCA is creating an opening to change how we work. #marketaccess #pharmaceutical #hta CCX World Evidence, Pricing and Access Congress

Only 1 week to go! Are you attending the World Evidence, Pricing and Access Congress next week? Let’s Connect. The CCX team will be based at booth #142 and we are looking forward to meeting with industry peers, thought leaders and innovators. Stop by our booth or drop us a message to schedule a time to meet the team and discuss how our software can support you with #marketaccess! #EPAConf #pricing